SG Americas Securities LLC Has $523,000 Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

SG Americas Securities LLC grew its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 85.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 44,838 shares of the company’s stock after acquiring an additional 20,694 shares during the period. SG Americas Securities LLC’s holdings in Intellia Therapeutics were worth $523,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Renaissance Technologies LLC acquired a new stake in Intellia Therapeutics during the 2nd quarter worth approximately $866,000. Sei Investments Co. lifted its holdings in shares of Intellia Therapeutics by 24.7% during the second quarter. Sei Investments Co. now owns 9,282 shares of the company’s stock worth $208,000 after buying an additional 1,837 shares in the last quarter. Thrivent Financial for Lutherans bought a new stake in shares of Intellia Therapeutics in the second quarter valued at about $679,000. Algert Global LLC grew its stake in shares of Intellia Therapeutics by 307.0% in the second quarter. Algert Global LLC now owns 68,372 shares of the company’s stock valued at $1,530,000 after acquiring an additional 51,572 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new position in Intellia Therapeutics during the second quarter worth about $449,000. Institutional investors own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on NTLA. Morgan Stanley downgraded shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $56.00 to $11.00 in a report on Monday, January 27th. Wedbush reissued a “neutral” rating and set a $10.00 price target (down previously from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. Chardan Capital lifted their price objective on Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a report on Monday, November 18th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. Finally, Citigroup decreased their price target on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $48.71.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $10.32 on Friday. The company’s 50 day moving average price is $12.26 and its two-hundred day moving average price is $17.62. The firm has a market capitalization of $1.05 billion, a P/E ratio of -1.90 and a beta of 1.83. Intellia Therapeutics, Inc. has a fifty-two week low of $9.25 and a fifty-two week high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. The company’s revenue was down 24.1% compared to the same quarter last year. During the same period last year, the business earned ($1.38) EPS. On average, analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Insider Activity

In related news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 29,000 shares of company stock valued at $352,551 over the last quarter. 3.20% of the stock is owned by company insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.